# US 7,611,833 B2 · Yeast genes that affect viral replication

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,833 B2
- Document ID: US7611833B2
- Status: Granted
- Kind: B2
- Application number: 10/618,896
- Filed: 2003-07-14
- Published: 2006-11-02
- Granted: 2009-11-03
- Earliest claimed: 2001-01-12
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Paul G. Ahlquist; Masayuki Ishikawa; Juana Diez; Duane B. Price; Wai-Ming Lee
- Web page: https://patentgrep.com/patent/US7611833B2

## CPC

- C07K 14/395: from Saccharomyces
- C12N 9/0083: {Miscellaneous (1.14.99)}
- C12Q 1/25: involving enzymes not classifiable in groups C12Q1/26 {- C12Q1/66}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An antiviral agent comprising an altered MAB1, MAB2, MAB3, or OLE1 gene, gene homologs or related genes is disclosed. In another embodiment, the present invention is a method of creating a virus resistant organism comprising creating a transgenic organism comprising an antiviral agent selected from the group of altered MAB1 genes, MAB2 genes, MAB3 genes or OLE1 genes, homologs of these genes, related genes and combinations of these genes and homologs.

## Claims

### Claim 1

A method of evaluating a substance as a positive strand RNA antiviral agent, comprising the steps of
a) exposing a substance to a yeast or mammalian Δ9 fatty acid desaturase enzyme, and
b) evaluating the effect of the substance on the stability of the enzyme, wherein decrease in stability indicates that the substance is an antiviral agent against positive strand RNA virus.

### Claim 2

A method of evaluating a substance as a positive strand RNA antiviral agent, comprising the steps of
a) exposing a substance to a yeast or mammalian Δ9 fatty acid desaturase enzyme, and
b) evaluating the effect of the substance on the activity of the enzyme, wherein the inhibition of activity indicates that the substance is an antiviral agent against positive strand RNA virus.

### Claim 3

A method of evaluating a substance as a positive strand RNA antiviral agent, comprising the steps of
a) exposing a substance to yeast OLE1 desaturase enzyme, and
b) evaluating the effect of the substance on the stability of the enzyme, wherein decrease in stability indicates that the substance is an antiviral agent against positive strand RNA virus.

### Claim 4

A method of evaluating a substance as a positive strand RNA antiviral agent, comprising the steps of
a) exposing a substance to a yeast OLE1 desaturase enzyme, and
b) evaluating the effect of the substance on the activity of the enzyme, wherein the inhibition of activity indicates that the substance is an antiviral agent against positive strand RNA virus.